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E-mail addresses: lavix@inwind.it (L. Nardinocchi),Homeodomain-interacting protein kinase-2 (HIPK2) is a crucial regulator of p53 apoptotic function
by phosphorylating serine 46 (Ser46) in response to DNA damage. In tumors with wild-type p53, its
tumor suppressor function is often impaired by MDM2 overexpression that targets p53 for proteaso-
mal degradation. Likewise, MDM2 targets HIPK2 for protein degradation impairing p53-apoptotic
function. Here we report that zinc antagonised MDM2-induced HIPK2 degradation as well as p53
ubiquitination. The zinc inhibitory effect on MDM2 activity leads to HIPK2-induced p53Ser46 phos-
phorylation and p53 pro-apoptotic transcriptional activity. These results suggest that zinc deriva-
tives are potential molecules to target the MDM2-induced HIPK2/p53 inhibition.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
P53 is a potent tumor suppressor gene and one of the key play-
ers in apoptosis signaling [1]. P53 activation is regulated through
speciﬁc posttranslational modiﬁcations, leading to p53 transcrip-
tional activation of target genes [2]. Because of its critical function,
p53 is frequently targeted for inactivation and suffers disabling
mutations or deletions in about 50% of all malignant tumors. The
other half of human cancers express wild-type p53 protein that
however, can be inactivated by deregulation of regulatory proteins
[3]. An important mechanism that regulates p53-apoptotic func-
tion involves MDM2 oncogene by means of its E3 ubiquitin ligase
activity that targets p53 for proteasomal degradation [4]. DNA-
damage-induced phosphorylation of its N-terminus contributes
to p53 stability by preventing MDM2 from degrading it [5].
Homeodomain-interacting protein kinase-2 (HIPK2) was identiﬁed
as a p53-interacting protein [6,7] that speciﬁcally phosphorylates
p53 at Ser46 for transcriptional activation of pro-apoptotic factors
such as p53AIP1, PIG3, Bax, Noxa, Puma and KILLER/DR5 [7–9], as
well as for the repression of the anti-apoptotic factor galectin-3chemical Societies. Published by E
mental Oncology, Molecular
Regina Elena”, 00158 Rome,
gdorazi@unich.it (G. D’Orazi).[10]. Moreover, HIPK2-induced p53Ser46 phosphorylation pre-
vents the MDM2-mediated p53 ubiquitination recovering p53
apoptotic function [11]. Therefore, preserving HIPK2 function is
crucial for p53 apoptotic activity.
MDM2 is not only a p53 inhibitor but also contributes to mod-
ulate the p53-mediated biological outcomes (i.e., cell cycle arrest
versus apoptosis) by regulating HIPK2. In response to non-lethal
DNA damage, p53-activated MDM2 inhibits the p53 apoptotic
pathway by targeting HIPK2 at residue lysine 1182 for proteasomal
degradation [12]. It is worth noting that the mdm2 gene is ampli-
ﬁed in a signiﬁcant proportion of human tumor types, thereby
contributing to tumor progression by efﬁciently reducing the avail-
ability of a functional p53 as well as most likely the availability of
its apoptotic activator HIPK2. Several approaches have been tested,
leading to the discovery of small molecules that can restore p53
function in tumor cells by targeting MDM2 through different
mechanisms [13]. This prompted us to evaluate whether it would
be possible to restore p53 apoptotic function by reactivating HIPK2
in the presence of MDM2.
2. Materials and methods
2.1. Cell culture and reagents
Human embryo kidney 293 and human colon carcinomaHCT116
cells weremaintained in DMEM (Life Technology-Invitrogen), whilelsevier B.V. All rights reserved.
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cells HeLa, and human lung cancer H1299 (p53 null) cells were
maintained in RPMI-1640 (Life Technology-Invitrogen), all supple-
mented with 10% heat-inactivated fetal bovine serum plus gluta-
mine and antibiotics in humidiﬁed atmosphere with 5% CO2 at
37 C.
Treatments: cells were incubated with 100 lM ZnCl2, 200 lM
Cobalt Chloride (CoCl2, hypoxia mimetic), 10 lmol/l Nutlin-3
(Cayman), and 5-10 lmol/l proteasome inhibitor MG132 (Biomol
Research Laboratories) for the indicated time.
2.2. Transient transfection and vectors
Cells were plated in 60 mm Petri dishes and, the day after,
transfected with the modiﬁed version of the calcium phosphate
procedure or the cationic polymer LipofectaminePlus method
(Invitrogen), according to the manufacturer’s instructions.
Expression vectors used were: wild-type HIPK2-Flag [7] and
mutant HIPK2-K1182R-Flag (MDM2-degradation resistant) [12],
human HA-MDM2 (kindly provided by M. Oren, Weizmann Insti-
tute of Science, Rehovor, Israel), and pCAG3.1wtp53 (kindly pro-
vided by E. Appella, NIH, Bethesda, MD, USA).
2.3. Western immunoblotting and ubiquitination
For Western immunoblotting, total cell extracts were
prepared by incubating at 4 C for 30 min in lysis buffer as
reported [11] and resolved by SDS–polyacrylamide gel electro-
phoresis. Proteins were transferred to a polyvinylidene diﬂuo-
ride (PVDF) membrane (Millipore). Immunoblottings were
performed with: mouse monoclonal anti-p53 (DO1), rabbit poly-
clonal anti-p53 (FL393), mouse monoclonal anti-MDM2 (Ab1),
rabbit polyclonal anti-p21Waf1 (all from Santa Cruz Biotechnol-
ogy), rabbit polyclonal anti-phospho-Ser46 (Cell Signaling Tech-
nology), rabbit polyclonal anti-HIPK2 (kindly provided by M.L.
Schmitz, Justus-Liebig-University, Giessen, Germany), mouse
monoclonal anti-Flag (M2, Sigma, Bio-Sciences), rat polyclonal
anti-HA (Roche Diagnostic), mouse monoclonal anti-tubulin
(Immunological Sciences), and mouse monoclonal anti-Hsp70
(Stressgene).
P53 ubiquitination was performed essentially as described [11].
Brieﬂy, H1299 cells were co-transfected with 1 lg pCAG3.1wtp53
and 4 lg HA-MDM2 expression vectors and 24 h later treated with
ZnCl2 and 10 lM MG132 for, respectively 16 and 8 h. Equal
amounts of total cell extracts were immunoprecipitated with
mouse monoclonal anti-p53 antibody (DO1) preadsorbed to pro-
tein G-agarose (Pierce). For endogenous HIPK2 ubiquitination as-
say, RKO cells were treated with ZnCl2 for 24 h, CoCl2 and 5 lM
MG132 for 16 h. Equal amounts of total cell extracts were immu-
noprecipitated with rabbit polyclonal anti-HIPK2 antibody pread-
sorbed to protein G-agarose (Pierce). Immunocomplexes were
collected by centrifugation, separated by SDS–PAGE, and blotted
onto nitrocellulose membrane (Bio-Rad, Hercules, CA, USA). Immu-
noreactivity was detected by enhanced chemiluminescence kit
(ECL; Amersham).
2.4. Luciferase assay
Cells were co-transfected with expression vectors along with
the luciferase reporter gene driven by the p53-dependent
promoter Noxa-luc (kindly provided by T. Taniguchi, University
of Tokyo, Japan) vector. Transfection efﬁciency was normalized
with a co-transfected b-galactosidase plasmid. Luciferase activity
was assayed on whole cell extract and the luciferase values
were normalized to b-galactosidase activity and protein
content.2.5. Reverse transcription polymerase chain reaction (RT-PCR)
Cells were harvested in TRIzol reagent (Invitrogen) and total
RNA was isolated following the manufacturer’s instructions. The
ﬁrst strand cDNA and the semi-quantitative RT-PCRs were carried
out essentially as described [14]. PCR products were run on a 2%
agarose gel and visualized by ethidium bromide staining using
UV light. The housekeeping glyceraldehydes-3-phosphate dehy-
drogenase (GAPDH) or aldolase-A (ald-A) mRNAs were used as
internal control.
2.6. TUNEL assay and immunoﬂuorescence
For TUNEL assay, 4  104 cells were spun on a slide by cytocen-
trifugation and subsequently ﬁxed in 4% paraformaldehyde for
30 min at room temperature. The samples were permeabilized
and then incubated in the TUNEL reaction mix for 1 h at 37 C
according to the manufacture’s instructions (Roche, Germany).
Cells were counter-stained with Hoechst 33 342 before analysis
with a ﬂuorescent microscope (Zeiss).
For indirect immunoﬂuorescence, HeLa cells were transfected
with HIPK2-Flag expression vector and 24 h after transfection trea-
ted with 100 lM ZnCl2 and 200 lM CoCl2 for 24 h and then ﬁxed in
methanol/acetone (1:1). Dried cells were blocked for 30 min at
room temperature in phosphate-buffered saline containing 10%
(v/v) goat serum, incubated with primary anti-Flag antibody at
4 C for 16 h and for 45 min with an appropriate ﬂuorochrome-
conjugated secondary antibody. Chromosomal DNA was visualized
by DAPI staining, stained cells were mounted on glass slides and
examined using a confocal laser microscope (Nikon Eclipse).
2.7. Statistical analysis
All experiment unless indicated were performed at least three
times. All experimental results were expressed as the arithmetic
mean and standard deviation (S.D.) of measurements was shown.
Student’s t-test was used for statistical signiﬁcance of the differ-
ences between treatment groups, determined as P < 0.05.
3. Results
3.1. MDM2-induced downregulation of HIPK2 and inhibition of
p53Ser46 phosphorylation, are rescued by zinc treatment
In order to identify natural compounds that restore HIPK2 func-
tion, the effect of zinc was investigated. 293 cells were co-transfec-
ted with HIPK2-Flag or the K1182R-Flag mutant and MDM2-HA
expression vectors and treated with zinc. As shown in Fig. 1, HIPK2
expression induced p53Ser46 phosphorylation (lane 2) while
MDM2 co-transfection induced HIPK2 downregulation and abol-
ishment of p53Ser46 phosphorylation (lane 3); interestingly, the
MDM2-induced HIPK2 downregulation was completely rescued
by zinc treatment with re-establishment of HIPK2-induced
p53Ser46 phosphorylation and downregulation of MDM2 levels
(lane 4). As expected, the MDM2 degradation-resistant HIPK2-
K1182R mutant induced p53Ser46 phosphorylation (Fig. 1, lane
5) and was not downregulated by MDM2 (lane 6) nor its activity
towards p53Ser46 phosphorylation was further affected by zinc
treatment (lane 7).
3.2. Reactivation of HIPK2-induced p53 transcriptional and apoptotic
activities
The clear effect of zinc on HIPK2 stability and p53Ser46 phos-
phorylation in the presence of MDM2 prompted us to evaluate
its biological consequences. First, the p53 responsive reporter
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Fig. 1. MDM-2-dependent downregulation of HIPK2 levels and HIPK2-dependent
p53Ser46 phosphorylation are rescued by zinc. 293 cells were co-transfected with
HIPK2-Flag or HIPK2-K1182R-Flag (2 lg) along with HA-MDM2 (6 lg) expression
vectors and 16 h after transfection treated with 100 lM ZnCl2 for 24 h. Anti-tubulin
was used as protein loading control.
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activity was inhibited by MDM2 and efﬁciently restored by zinc
(Fig. 2A). Consequently, HIPK2-induced p53 pro-apoptotic tran-
scription was inhibited by MDM2 but strongly relieved by zinc
treatment (Fig. 2B). Finally, we observed a consistent inhibitory ef-
fect of MDM2 on HIPK2-induced TUNEL positivity while MDM2
was not able to inhibit the HIPK2-K1182R mutant, as reported
[15]; of note, zinc relapsed the MDM2 inhibitory effect on HIPK2
activity and restored HIPK2-induced apoptosis (Fig. 2C).
3.3. Zinc neutralizes the MDM2 ubiquitin ligase activity
Then, we took advantage of Nutlin-3 molecule that binds
MDM2 in the p53 pocket and inhibits p53 degradation restoring0
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Fig. 2. Zinc treatment counteracts the MDM2-dependent HIPK2 inhibition and restores p
Flag (2 lg) and HA-MDM2 (6 lg) expression vectors along with Noxa-luc reporter plasm
was assayed. Data are the mean ± S.D. of three independent experiments performed in
transcribed from 293 cells treated as in (A), for semi-quantitative RT-PCR analysis. GAPDH
K1182R-Flag (2 lg) along with HA-MDM2 (6 lg) expression vectors and 16 h after tra
positive cells over Hoechst-stained nuclei. Standard deviation of three independent expits activity, although it may not induce p53-dependent apoptosis
[15,16]. Nutlin-3 preserves MDM2 E3 ligase activity [15], thus it in-
duces HIPK2 downregulation inhibiting p53Ser46 apoptotic activ-
ity [17]. As shown in Fig. 3A, Nutlin-3 treatment markedly
downregulated HIPK2 levels and induced p21Waf1 and MDM2, as
previously reported [17]. The effect of MDM2 antagonism was re-
verted by zinc that neutralized the Nutlin-3-induced HIPK2 down-
regulation (Fig. 3A). Next, H1299 cells were co-transfected with
p53 and MDM2 expression vectors in the presence of MG132 and
assayed by p53 immunoprecipitation. Co-transfection of p53 and
MDM2 revealed a ladder of p53-speciﬁc high molecular weight
bands indicative of protein ubiquitination (Fig. 3B), while, zinc
strongly reduced the extent of p53 ubiquitination (Fig. 3B, lower
panel). Finally, the inhibition of p53-induced Noxa-luc activity by
MDM2 co-expression was signiﬁcantly counteracted by zinc
(Fig. 3C).
3.4. The hypoxia-dependent HIPK2 cytoplasmic delocalization and
ubiquitination is counteracted by zinc
We reported a chemical hypoxia model where HIPK2 downreg-
ulation correlates with p53-induced MDM2 expression [18]. Indi-
rect immunoﬂuorescence analysis of ectopic HIPK2 showed the
usual localization as nuclear dots [7], while cobalt treatment
strongly delocalized HIPK2 into the cytoplasm (Fig. 4A). Zinc pre-
treatment, completely counteracted the cobalt effect on HIPK2
subcellular localization, maintaining the nuclear dotted appear-
ance (Fig. 4A). Western immunoblotting showed that cobalt treat-
ment induced MDM2 levels, that were downregulated by zinc
supplementation (Fig. 4B). In agreement, MDM2 RNA levels, which
were induced by cobalt as reported [18], were reduced by zinc
treatment. Finally, the cobalt-induced HIPK2 ubiquitination was
strongly inhibited by zinc treatment, in agreement with our
hypothesis that the cobalt inhibition at least in part is affecting
the MDM2 ligase activity (Fig. 4C).0
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Fig. 3. The MDM2-induced p53 ubiquitination is counteracted by zinc. (A) RKO (left panel) and HCT116 (right panel) cells were treated with 10 lM Nutlin-3 and ZnCl2 for,
respectively, 48 and 24 h. Equal amounts of total cell extracts were assayed for Western immunoblotting. Anti-tubulin was used as protein loading control. (B) For p53
ubiquitination, H1299 cells were co-transfected with CMVp53 (1 lg) and HA-MDM2 (4 lg) expression vectors and 16 h after transfection treated with ZnCl2 and 10 lM
proteasome inhibitor MG132 for, respectively, 24 and 8 h. Equal amounts of total cell extracts were subjected to immunoprecipitation (IP) analysis with anti-p53 monoclonal
antibody (DO1) and Western immunoblotting (IB) with anti-p53 polyclonal antibody (FL393). The position of the p53-ubiquitin (p53-Ubn) conjugates is indicated. The lower
panel shows Western immunoblotting of 1/10 of total cell extracts (Input). Anti-tubulin was used as protein loading control. (C) H1299 cells were co-transfected with CMV-
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In the present study we disclosed a novel way to unlock the
MDM2-p53 feedback loop and unveiled a way to counteract the
MDM2-induced HIPK2 downregulation that consequently restored
also p53 apoptotic transcriptional activity.
HIPK2 is a multifunctional protein kinase that positively acti-
vates p53 pro-apoptotic function in response to apoptotic stress
signals [7,19,20] and also exerts its antitumor activity by modulat-
ing the transcription activity of molecules involved in tumor pro-
gression, angiogenesis and chemoresistance, including HIF-1a
and b-catenin [21]. These ﬁndings suggest the potential role of
HIPK2 as cancer biomarker whose expression may contribute to
p53 activity and the decision on anti-tumor therapies. Indeed we
previously showed a correlation between low HIPK2 expression
and bad outcome in wild-type p53 expressing colon cancer tumors
[14]. HIPK2 cytoplasmic localization may also affect p53 apoptotic
function, following overexpression of oncogenes such as CBFb-
SMMHC in a leukemogenesis model [22,23], high-mobility groupA1 (HMGA1) [24] or b4 integrin in breast cancers [25]. HIPK2 can
be downregulated by several E3 ubiquitin ligases such as WD40-
repeat/SOCS box protein WSB-1, the RING family ligases Siah-1
and Siah-2 and, MDM2 oncogene [21]. Thus as p53 and MDM2 con-
stitute a reciprocal feedback loop, MDM2 and HIPK2 add an addi-
tional inhibitory arm to this loop to facilitate a more ﬁne tuning
of the regulation of apoptosis.
We recently found that, upon chemical hypoxia, MDM2 is in-
duced leading to HIPK2 downregulation and inhibition of p53
apoptotic activity in response to drugs [18]. Interestingly, we
found that zinc supplementation reverses the hypoxia-induced
HIPK2 downregulation which prompted us to further evaluate
the molecular mechanisms of reversible HIPK2 inactive/active
switch. Here, we showed that zinc relapsed the MDM2-induced
HIPK2 downregulation, likely counteracting the MDM2 E3 ubiqui-
tin ligase activity. This ﬁnding was obtained upon MDM2/HIPK2
co-transfection and by Nutlin-3 treatment (Fig. 4A), which has
been shown to downregulate HIPK2 levels [17] without affecting
MDM2 ubiquitin ligase activity [15]. The negative role of zinc on
Hsp70
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Fig. 4. The hypoxia-dependent HIPK2 cytoplasmic delocalization and ubiquitination is counteracted by zinc. (A) HeLa cells were transfected with HIPK2-Flag and treated with
ZnCl2 and CoCl2 alone or in combination for, respectively, 24 and 16 h. HIPK2 localization was visualized by indirect immunoﬂuorescence with anti-Flag antibody.
Overlapping localization in merged pictures is shown in yellow and chromosomal DNA was stained with DAPI. (B) RKO were treated with ZnCl2 and CoCl2 for, respectively, 24
and 16 h and then subjected to Western immunoblotting (left panel) or semi-quantitative RT-PCR analysis (right panel). Anti-Hsp70 was used as protein loading control and
GAPDHwas used as internal RT-PCR control. (C) For endogenous HIPK2 ubiquitination, RKO were treated with ZnCl2 and CoCl2 for, respectively, 24 and 16 h in the presence of
MG132 for 16 h. Equal amounts of total cell extracts were subjected to immunoprecipitation (IP) analysis. The position of the HIPK2-ubiquitin (HIPK2-Ubn) conjugates is
indicated.
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duced p53 ubiquitination (Fig. 3B) and indirectly on hypoxia-in-
duced HIPK2 ubiquitination (Fig. 4C). Once HIPK2 is stabilised,
it may inhibit MDM2 transcription and protein through p53-
dependent [11] or p53-independent mechanisms [26]; thus, here
MDM2 downregulation was observed upon HIPK2 reactivation by
zinc. Hence, as depicted in Fig. 5, zinc can interfere with the inter-
play between HIPK2, p53 and MDM2 favouring HIPK2 stabiliza-
tion and induction of p53 apoptotic activity with inhibition of
MDM2 function. However, as HIPK2 is a protein subjected to pro-
teasome degradation [21] it would be interesting to evaluate in
the future whether zinc can also inhibit other E3 ubiquitin ligases
acting on HIPK2, in light of the ﬁnding that zinc may inhibit pro-
teasome-dependent proteolysis [27].HIPK2
p53
Zinc
MDM2
Fig. 5. Proposed model of HIPK2/p53/MDM2 interplay. The autoregulatory control
loop whereas p53 induces Mdm2 which on the contrary inhibits p53 [5,6] can be
interrupted by zinc. The zinc-induced MDM2 downregulation relieves the MDM2-
induced HIPK2 degradation [15] and HIPK2 is now available for p53Ser46 phos-
phorylation [10] and for MDM2 phosphorylation and proteasomal degradation [26].Acknowledgments
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